An enhancing brainstem lesion in a patient with a history of worldwide travel

K. L. Roos; L. A. Gerdes; K. Kurz; H. Kretzschmar; T. Kümpfel; J. E. Parisi; B. M. Keegan

doi:10.1212/WNL.0b013e318236eec2

An enhancing brainstem lesion in a patient with a history of worldwide travel

K. L. Roos, L. A. Gerdes, K. Kurz, H. Kretzschmar, T. Kümpfel, J. E. Parisi, B. M. Keegan

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	1756-1760
Number of pages	5
Journal	Neurology
Volume	77
Issue number	19
DOIs	https://doi.org/10.1212/WNL.0b013e318236eec2
State	Published - Nov 8 2011

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.0b013e318236eec2

Cite this

@article{314c2062adb14fec9712ffb7e7945a07,

title = "An enhancing brainstem lesion in a patient with a history of worldwide travel",

author = "Roos, {K. L.} and Gerdes, {L. A.} and K. Kurz and H. Kretzschmar and T. K{\"u}mpfel and Parisi, {J. E.} and Keegan, {B. M.}",

note = "Funding Information: Dr. Roos receives funding for travel from the AAN and other universities; serves as Editor-in-Chief of Seminars in Neurology; receives royalties from the publications of 4 textbooks; and gave expert testimony but all monies went to the Department of Neurology at the Indiana University School of Medicine. Dr. Gerdes and Dr. Kurz report no disclosures. Dr. Kretzschmar served on the scientific advisory board for Acta Neuropathologica, Neurogenetics, Brain Pathology, and Translational Neuroscience; receives royalties from the publication of the book Prions in Humans and Animals; receives research support from Federal Ministry of Education and Research, BMG, European Union, and German Research Foundation (DFG); and gave expert testimony for B. Braun Melsungen AG. Dr. K{\'u}mpfel received honoraria for lectures from Bayer Schering Pharma, Teva Pharmaceutical Industries Ltd, Merck Serono, and Biogen Idec (not funded by industry); received funding for travel from Bayer Schering Pharma, Teva Pharmaceutical Industries Ltd, Merck Serono, Novartis, and Biogen Idec; and received research support from Bayer Schering Pharma (not related to this study). Dr. Parisi serves on scientific advisory boards for the US Government Defense Health Board and the Subcommittee for Laboratory Services and Pathology; serves as a Section Editor for Neurology; receives royalties from the publication of Principles & Practice of Neuropathology, 2nd ed. (Oxford University Press, 2003); and receives research support from the NIH. Dr. Keegan serves as Clinical Pathological Conference Section Co-Editor for Neurology and Neurology podcast panel and Chief Editor for eMedicine; and has served as a consultant for Novartis.",

year = "2011",

month = nov,

day = "8",

doi = "10.1212/WNL.0b013e318236eec2",

language = "English (US)",

volume = "77",

pages = "1756--1760",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "19",

}

TY - JOUR

T1 - An enhancing brainstem lesion in a patient with a history of worldwide travel

AU - Roos, K. L.

AU - Gerdes, L. A.

AU - Kurz, K.

AU - Kretzschmar, H.

AU - Kümpfel, T.

AU - Parisi, J. E.

AU - Keegan, B. M.

N1 - Funding Information: Dr. Roos receives funding for travel from the AAN and other universities; serves as Editor-in-Chief of Seminars in Neurology; receives royalties from the publications of 4 textbooks; and gave expert testimony but all monies went to the Department of Neurology at the Indiana University School of Medicine. Dr. Gerdes and Dr. Kurz report no disclosures. Dr. Kretzschmar served on the scientific advisory board for Acta Neuropathologica, Neurogenetics, Brain Pathology, and Translational Neuroscience; receives royalties from the publication of the book Prions in Humans and Animals; receives research support from Federal Ministry of Education and Research, BMG, European Union, and German Research Foundation (DFG); and gave expert testimony for B. Braun Melsungen AG. Dr. Kúmpfel received honoraria for lectures from Bayer Schering Pharma, Teva Pharmaceutical Industries Ltd, Merck Serono, and Biogen Idec (not funded by industry); received funding for travel from Bayer Schering Pharma, Teva Pharmaceutical Industries Ltd, Merck Serono, Novartis, and Biogen Idec; and received research support from Bayer Schering Pharma (not related to this study). Dr. Parisi serves on scientific advisory boards for the US Government Defense Health Board and the Subcommittee for Laboratory Services and Pathology; serves as a Section Editor for Neurology; receives royalties from the publication of Principles & Practice of Neuropathology, 2nd ed. (Oxford University Press, 2003); and receives research support from the NIH. Dr. Keegan serves as Clinical Pathological Conference Section Co-Editor for Neurology and Neurology podcast panel and Chief Editor for eMedicine; and has served as a consultant for Novartis.

PY - 2011/11/8

Y1 - 2011/11/8

UR - http://www.scopus.com/inward/record.url?scp=82955243942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955243942&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e318236eec2

DO - 10.1212/WNL.0b013e318236eec2

M3 - Article

C2 - 22067962

AN - SCOPUS:82955243942

SN - 0028-3878

VL - 77

SP - 1756

EP - 1760

JO - Neurology

JF - Neurology

IS - 19

ER -

An enhancing brainstem lesion in a patient with a history of worldwide travel

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this